Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.5.3.6 - arginine deiminase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abscess
Staphylococcus aureus Small Colony Variants (SCVs): a road map for the metabolic pathways involved in persistent infections.
Acquired Immunodeficiency Syndrome
Arginine deiminase gene of an AIDS-associated mycoplasma, Mycoplasma incognitus.
Adenocarcinoma
Arginine deiminase originating from Lactococcus lactis ssp. lactis American Type Culture Collection (ATCC) 7962 induces G1-phase cell-cycle arrest and apoptosis in SNU-1 stomach adenocarcinoma cells.
Arthritis
[Protein arginine deiminase of oral microbiome plays a causal role in the polyarthritis rheumatoid initiating].
Arthritis, Rheumatoid
Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans.
Lack of Association among Peptidyl Arginine Deiminase Type 4 Autoantibodies, PADI4 Polymorphisms, and Clinical Characteristics in Rheumatoid Arthritis.
Response to 'Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study'.
[Peptidyl arginine deiminase 4 participates in the pathogenesis of rheumatoid arthritis by influencing histone methylation].
Breast Neoplasms
Arginine Deiminase Induces Immunogenic Cell Death and Is Enhanced by N-acetylcysteine in Murine MC38 Colorectal Cancer Cells and MDA-MB-231 Human Breast Cancer Cells In Vitro.
Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
Carcinogenesis
ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
Carcinoma
Development and characterization of macrophage hybridomas derived from murine peritoneal exudate cells.
Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.
Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
Carcinoma, Hepatocellular
A potential antitumor drug (arginine deiminase) reengineered for efficient operation under physiological conditions.
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients.
An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo.
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-?B signaling.
Arginine deiminase expressed in vivo, driven by human telomerase reverse transcriptase promoter, displays high hepatoma targeting and oncolytic efficiency.
Arginine deiminase, a potential anti-tumor drug.
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
Blocking autophagy enhanced leukemia cell death induced by recombinant human arginase.
Decreasing the immunogenicity of arginine deiminase enzyme via structure-based computational analysis.
Directed Evolution of an Antitumor Drug (Arginine Deiminase PpADI) for Increased Activity at Physiological pH.
Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers.
Expression of arginine deiminase from Pseudomonas plecoglossicida CGMCC2039 in Escherichia coli and its anti-tumor activity.
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation.
Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.
Protein engineering of the antitumor enzyme PpADI for improved thermal resistance.
Rapid evolution of arginine deiminase for improved anti-tumor activity.
Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma.
Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
Carcinoma, Renal Cell
Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
Cerebellar Ataxia
Cognitive impairment in ARCA-1, a newly discovered pure cerebellar ataxia syndrome.
Cerebellar Diseases
Clinical and genetic study of autosomal recessive cerebellar ataxia type 1.
Colitis
Pegylated arginine deiminase downregulates colitis in murine models.
Colorectal Neoplasms
Arginine Deiminase Induces Immunogenic Cell Death and Is Enhanced by N-acetylcysteine in Murine MC38 Colorectal Cancer Cells and MDA-MB-231 Human Breast Cancer Cells In Vitro.
Dental Caries
A Highly Arginolytic Streptococcus Species That Potently Antagonizes Streptococcus mutans.
Caries-free subjects have high levels of urease and arginine deiminase activity.
Cleansing effect of acidic L-arginine on human oral biofilm.
Could alkali production be considered an approach for caries control?
Diversity in Antagonistic Interactions between Commensal Oral Streptococci and Streptococcus mutans.
Effect of arginine on the growth and biofilm formation of oral bacteria.
Effects of Arginine on Growth, Virulence Gene Expression, and Stress Tolerance by Streptococcus mutans.
In Vivo Colonization with Candidate Oral Probiotics Attenuates Colonization and Virulence of Streptococcus mutans.
Oral Microbiome Metabolism: From "Who Are They?" to "What Are They Doing?".
The effect of arginine on oral biofilm communities.
Dental Plaque
Correlations of oral bacterial arginine and urea catabolism with caries experience.
Effects of Arginine on Growth, Virulence Gene Expression, and Stress Tolerance by Streptococcus mutans.
Fluoride, triclosan and organic weak acids as modulators of the arginine deiminase system in biofilms and suspension cells of oral streptococci.
In Vivo Colonization with Candidate Oral Probiotics Attenuates Colonization and Virulence of Streptococcus mutans.
Diphtheria
Anticancer Activity of Bacterial Proteins and Peptides.
Dysarthria
Clinical and genetic study of autosomal recessive cerebellar ataxia type 1.
Epstein-Barr Virus Infections
Arginine Methyltransferases Are Regulated by Epstein-Barr Virus in B Cells and Are Differentially Expressed in Hodgkin's Lymphoma.
Giardiasis
Multilevel Approach for the Treatment of Giardiasis by Targeting Arginine Deiminase.
Polymeric immunoglobulin receptor in intestinal immune defense against the lumen-dwelling protozoan parasite Giardia.
Glioblastoma
Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
Glioma
A Phase I study of pegylated arginine deiminase (pegargiminase), cisplatin and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma.
Hepatitis C
Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.
Hepatitis C, Chronic
Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.
Hypersensitivity
?ccurrence of bacterial spot caused by Xanthomonas arboricola pv. pruni on peach and apricot in Serbia.
A New Disease, Bacterial Leaf Spot of Rape, Caused by Atypical Pseudomonas viridiflava in South Korea
A New Disease, Bacterial Leaf Spot of Rape, Caused by Atypical Pseudomonas viridiflava in South Korea.
Brown Blotch Caused by Pseudomonas tolaasii on Cultivated Pleurotus eryngii in Spain.
First Report of Bacterial Blight of Sugar Beet Caused by Pseudomonas syringae pv. aptata in Georgia, USA.
First Report of Bacterial Canker Caused by Pseudomonas syringae pv. morsprunorum Race 1 on Cherry in Chile.
First Report of Bacterial Canker of Kiwifruit Caused by Pseudomonas syringae pv. actinidiae in Turkey.
First Report of Bacterial Leaf Spot Caused by Pseudomonas syringae pv. aptata on Swiss Chard, Beta vulgaris subsp. vulgaris, in Arizona.
First report of bacterial leaf spot disease on sunflower (Helianthus annuus) caused by Pseudomonas viridiflava in South Korea.
First Report of Bacterial Leaf Spot of Coriander Caused by Pseudomonas syringae pv. coriandricola in India.
First Report of Bacterial Leaf Spot of Witloof, Caused by Pseudomonas cichorii in Korea.
First Report of Bacterial Leaf Spot on Cichorium intybus Caused by Pseudomonas cichorii in Florida.
First Report of Copper-Tolerant Pseudomonas syringae pv. tomato in Virginia.
First Report of Leaf Spot Caused by Pseudomonas cichorii on Coreopsis lanceolata in Italy.
First Report of Pseudomonas syringae pv. syringae Causing Bacterial Leaf Spots of Oil Pumpkin (Cucurbita pepo) in Serbia.
First Report of Pseudomonas syringae pv. tomato Race 1 on Tomato in California.
First report of Pseudomonas syringae pv. tomato race 1 on tomato in California.
Pseudomonas viridiflava: An internal outsider of the Pseudomonas syringae species complex.
Hypotension
Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor alpha and endotoxin.
Infections
Anaerobic arginine metabolism of Mycobacterium tuberculosis is mediated by arginine deiminase (arcA), but is not essential for chronic persistence in an aerogenic mouse model of infection.
High-resolution transcriptomic analysis of the adaptive response of staphylococcus aureus during acute and chronic phases of osteomyelitis.
Identification and characterization of the arginine deiminase system of Streptococcus canis.
Role of arginine deiminase in thymic atrophy during experimental Streptococcus pyogenes infection.
The Arginine Deiminase Pathway Impacts Antibiotic Tolerance during Biofilm-Mediated Streptococcus pyogenes Infections.
Leukemia
A potential antitumor drug (arginine deiminase) reengineered for efficient operation under physiological conditions.
Apoptotic cell death of human T lymphoblastoid cells induced by arginine deiminase.
Apoptotic effects of selected strains of lactic acid bacteria on a human T leukemia cell line are associated with bacterial arginine deiminase and/or sphingomyelinase activities.
Arginine deiminase enhances dexamethasone-induced cytotoxicity in human T-lymphoblastic leukemia CCRF-CEM cells.
Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis.
Leukemia, Myeloid, Acute
A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients.
Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.
Liver Neoplasms
Regression of hepatocellular cancer in a patient treated with arginine deiminase.
Lung Neoplasms
Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.
Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy.
Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer.
Lymphoma
L-arginine enhances arginine deiminase induced human lymphoma cell growth inhibition through NF-kBp65 and p53 expression in vitro.
Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.
Lymphoma, Large B-Cell, Diffuse
Abnormal behavior of gamma-committed B lymphocytes probed by a lymphocyte blastogenesis inhibitory factor in autoimmune MRL mice.
Identification and purification of arginine deiminase that originated from Mycoplasma arginini.
Malaria
Gateways to clinical trials.
Melanoma
A lymphocyte blastogenesis inhibitory factor (LBIF) reversibly arrests a human melanoma cell line, A375, at G1 and G2 phases of cell cycle.
A potential antitumor drug (arginine deiminase) reengineered for efficient operation under physiological conditions.
Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo.
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-?B signaling.
Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence and Glutamine Addiction.
Arginine deiminase, a potential anti-tumor drug.
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Decreasing the immunogenicity of arginine deiminase enzyme via structure-based computational analysis.
Deprivation of arginine by recombinant human arginase in prostate cancer cells.
Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.
Directed arginine deiminase evolution for efficient inhibition of arginine-auxotrophic melanomas.
Directed Evolution of an Antitumor Drug (Arginine Deiminase PpADI) for Increased Activity at Physiological pH.
Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers.
Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma.
Evaluation of Arginine Deiminase Treatment in Melanoma Xenografts Using (18)F-FLT PET.
Expression of arginine deiminase from Pseudomonas plecoglossicida CGMCC2039 in Escherichia coli and its anti-tumor activity.
Growth inhibition of human melanoma cells by a recombinant arginine deiminase expressed in Escherichia coli.
High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro.
Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma.
Improved method for expression and isolation of the Mycoplasma hominis arginine deiminase from the recombinant strain of Escherichia coli.
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation.
Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma.
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
Protein engineering of the antitumor enzyme PpADI for improved thermal resistance.
Rapid evolution of arginine deiminase for improved anti-tumor activity.
Recombinant Human Arginase Inhibits the In vitro and In vivo Proliferation of Human Melanoma by Inducing Cell Cycle Arrest and Apoptosis.
Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma.
Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4.
The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma.
[Mechanism of arginine deiminase activity by site-directed mutagenesis].
Melioidosis
A case of thoracic empyema due to suppurative melioidosis.
Mesothelioma
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase.
Mesothelioma, Malignant
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
Mycoplasma Infections
Detection of mycoplasma infection of mammalian cells.
Neoplasms
A Competitive Flow Cytometry Screening System for Directed Evolution of Therapeutic Enzyme.
A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients.
A potential antitumor drug (arginine deiminase) reengineered for efficient operation under physiological conditions.
Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
ADI, autophagy and apoptosis: metabolic stress as a therapeutic option for prostate cancer.
Amino Acid Degrading Enzymes and Autophagy in Cancer Therapy.
Amino Acid Uptake Measured by [18F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas.
Anticancer Activity of Bacterial Proteins and Peptides.
Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation.
Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-?B signaling.
Arginine deiminase enhances MCF-7 cell radiosensitivity by inducing changes in the expression of cell cycle-related proteins.
Arginine Deiminase Enzyme Evolving As A Potential Antitumor Agent.
Arginine deiminase expressed in vivo, driven by human telomerase reverse transcriptase promoter, displays high hepatoma targeting and oncolytic efficiency.
Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence and Glutamine Addiction.
Arginine deiminase, a potential anti-tumor drug.
Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth.
Arginine Deiminase: Current Understanding and Applications.
Arginine deiminase: recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug.
Arginine depletion by arginine deiminase does not affect whole protein metabolism or muscle fractional protein synthesis rate in mice.
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.
Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.
Arginine Metabolism in Bacterial Pathogenesis and Cancer Therapy.
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy.
Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2? Activity and Is Targetable by Pegylated Arginine Deiminase.
Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20.
Aspergillus nidulans thermostable arginine deiminase-Dextran conjugates with enhanced molecular stability, proteolytic resistance, pharmacokinetic properties and anticancer activity.
Biomimetic microbioreactor-supramolecular nanovesicles improve enzyme therapy of hepatic cancer.
Blocking autophagy enhanced leukemia cell death induced by recombinant human arginase.
Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini.
Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1? Degradation at the ASS1 promoter for ASS1 Derepression.
Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1?, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.
Citrullination of pyruvate kinase M2 by PADI1 and PADI3 regulates glycolysis and cancer cell proliferation.
Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors.
Comparative proteomic analysis reveals metabolic variability of probiotic Enterococcus durans during aerobic and anaerobic cultivation.
Comparative transcriptional analysis reveals distinct expression patterns of channel catfish genes after the first infection and re-infection with Aeromonas hydrophila.
Crystal structures of arginine deiminase with covalent reaction intermediates; implications for catalytic mechanism.
Decreasing the immunogenicity of arginine deiminase enzyme via structure-based computational analysis.
Deprivation of arginine by recombinant human arginase in prostate cancer cells.
Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.
Directed arginine deiminase evolution for efficient inhibition of arginine-auxotrophic melanomas.
Directed Evolution of an Antitumor Drug (Arginine Deiminase PpADI) for Increased Activity at Physiological pH.
Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers.
Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma.
Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor alpha and endotoxin.
Expression of arginine deiminase from Pseudomonas plecoglossicida CGMCC2039 in Escherichia coli and its anti-tumor activity.
Extrinsic nitric oxide donor partially reverses arginine deiminase induced cell growth inhibition through NFkappaB and Bcl-X L.
High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro.
Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20).
Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma.
Improved method for expression and isolation of the Mycoplasma hominis arginine deiminase from the recombinant strain of Escherichia coli.
In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini.
Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Insights into the modulation of optimum pH by a single histidine residue in arginine deiminase from Pseudomonas aeruginosa.
International multicentre observational study to evaluate the association between perioperative red blood cell transfusions and 1-year mortality after major cancer surgery (ARCA-1): study design, statistical analysis plan and study protocol.
Intracellular delivery of recombinant arginine deiminase (rADI) by heparin-binding hemagglutinin adhesion peptide restores sensitivity in rADI-resistant cancer cells.
Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM.
Molecular basis and current strategies of therapeutic arginine depletion for cancer.
Mono-PEGylation of a Thermostable Arginine-Depleting Enzyme for the Treatment of Lung Cancer.
MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma.
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration.
Pegylated arginine deiminase downregulates colitis in murine models.
Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.
Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
PEGylation and pharmacological characterization of a potential anti-tumor drug, an engineered arginine deiminase originated from Pseudomonas plecoglossicida.
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers.
Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.
Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced malignant solid tumors.
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.
Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line.
Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.
Protein engineering of the antitumor enzyme PpADI for improved thermal resistance.
Purification, immobilization, and biochemical characterization of l-arginine deiminase from thermophilic Aspergillus fumigatus KJ434941: Anticancer activity in vitro.
Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy.
Rapid evolution of arginine deiminase for improved anti-tumor activity.
Rational surface engineering of an arginine deiminase (an antitumor enzyme) for increased PEGylation efficiency.
Recombinant Bacillus caldovelox Arginase Mutant (BCA-M) Induces Apoptosis, Autophagy, Cell Cycle Arrest and Growth Inhibition in Human Cervical Cancer Cells.
Recombinant human arginase induced caspase-dependent apoptosis and autophagy in non-Hodgkin's lymphoma cells.
Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.
Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase.
RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells.
Selective extracellular arginine deprivation by a single injection of cellular non-uptake arginine deiminase nanocapsules for sustained tumor inhibition.
Single amino acid arginine starvation efficiently sensitizes cancer cells to canavanine treatment and irradiation.
Suppression of human immunodeficiency virus type 1 replication by arginine deiminase of Mycoplasma arginini.
Targeting arginine metabolism pathway to treat arginine-dependent cancers.
The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.
The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.
TRAIL stabilization and cancer cell sensitization to its pro-apoptotic activity achieved through genetic fusion with arginine deiminase.
Tumor growth inhibitory activity of a lymphocyte blastogenesis inhibitory factor.
[Mechanism of arginine deiminase activity by site-directed mutagenesis].
Neuroblastoma
Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation.
Depletion of arginine by recombinant arginine deiminase induces nNOS-activated neurotoxicity in neuroblastoma cells.
Ovarian Neoplasms
Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.
Pancreatic Neoplasms
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-?B signaling.
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Exploiting arginine auxotrophy with pegylated arginine deiminase (ADI-PEG20) to sensitize pancreatic cancer to radiotherapy via metabolic dysregulation.
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
Prostatic Neoplasms
Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.
Arginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy.
Cytoprotective effect of arginine deiminase on taxol-induced apoptosis in DU145 human prostate cancer cells.
Deprivation of arginine by recombinant human arginase in prostate cancer cells.
Pulmonary Fibrosis
Therapeutic targeting of argininosuccinate synthase 1 (ASS1)-deficient pulmonary fibrosis.
Retinoblastoma
Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma.
Sarcoma
A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Autoantibodies to PAD4 and BRAF in rheumatoid arthritis.
New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA.
Shock, Septic
Expression of enterotoxin-coding genes in methicillin-resistant Staphylococcus aureus strains isolated from Mexican haemodialysis patients.
Small Cell Lung Carcinoma
Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy.
Starvation
A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.
Amino Acid Uptake Measured by [18F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas.
Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1? Degradation at the ASS1 promoter for ASS1 Derepression.
Decreasing the immunogenicity of arginine deiminase enzyme via structure-based computational analysis.
Systems level profiling of arginine starvation reveals MYC and ERK adaptive metabolic reprogramming.
Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
Transcriptome analysis of the progressive adaptation of Lactococcus lactis to carbon starvation.
Stomach Neoplasms
Arginine deiminase originating from Lactococcus lactis ssp. lactis American Type Culture Collection (ATCC) 7962 induces G1-phase cell-cycle arrest and apoptosis in SNU-1 stomach adenocarcinoma cells.
Streptococcal Infections
Identification and characterization of the arginine deiminase system of Streptococcus canis.
Tooth Demineralization
Arginine Metabolism in Supragingival Oral Biofilms as a Potential Predictor of Caries Risk.
Tuberculosis
Anaerobic arginine metabolism of Mycobacterium tuberculosis is mediated by arginine deiminase (arcA), but is not essential for chronic persistence in an aerogenic mouse model of infection.
Urinary Bladder Neoplasms
Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2? Activity and Is Targetable by Pegylated Arginine Deiminase.
Vaginosis, Bacterial
Microecology, bacterial vaginosis and probiotics: perspectives for bacteriotherapy.
Virus Diseases
Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.